Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $72
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia maintains a 'Buy' rating on Intra-Cellular Therapies (NASDAQ:ITCI) and raises the price target from $71 to $72.
November 03, 2023 | 11:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst maintains a 'Buy' rating on Intra-Cellular Therapies and raises the price target to $72.
The 'Buy' rating maintained by Needham analyst Ami Fadia and the increase in price target from $71 to $72 indicates a positive outlook for Intra-Cellular Therapies. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100